eGlint Wins BioTools Innovator Capstone Event
The biosensor startup secures $250,000 for its rapid protein detection platform.
Updated on Oct. 15, 2026 in Biotech
Live Poll
Would you use an at-home diagnostic platform to monitor your protein biomarkers from your phone?
Biotech firm eGlint, Inc. took first place at the BioTools Innovator Capstone Event. The company was awarded $250,000 for its diagnostic platform that detects protein biomarkers from serum samples.
Why it matters
The platform aims to provide a diagnostic tool that is fast, simple, and affordable while maintaining the sensitivity levels of traditional ELISA testing. By utilizing existing real-time PCR machines, the technology offers a more accessible path for clinical diagnostic workflows.
The eGlint platform utilizes aptamers tagged with a signal-emitting fluorophore and a signal-blocking quencher to identify proteins within 10 minutes. It functions by using engineered beads in solution to facilitate faster mixing during analysis.
The players
eGlint, Inc.
This biotechnology company focuses on developing rapid biosensor platforms for protein biomarker detection.
The details
The technology leverages aptamer-based kits, which are currently being rolled out to biopharmaceutical firms for clinical trials. Designed to work with standard real-time PCR infrastructure, the system streamlines the detection process by simplifying the interaction between biomarkers and the sensor beads.
Timeline
2021: eGlint, Inc. was founded.
October 14, 2026: eGlint, Inc. won the BioTools Innovator pitch finals.
Q1 2027: The company plans to launch a process-monitoring panel for manufacturing.
The Tech Race
The transition toward faster protein detection reflects a broader industry shift away from the labor-intensive, multi-hour workflows characteristic of standard ELISA tests. Companies are increasingly racing to adapt existing laboratory infrastructure like PCR machines for multi-modal diagnostic capabilities.
For clinical laboratories and biopharmaceutical manufacturers, this platform offers a faster turnaround for results using hardware already present in many facilities. This could eventually lower the costs associated with diagnostic testing and drug manufacturing cycles.
The takeaway
This award highlights the growing emphasis on leveraging existing PCR equipment for new, high-speed diagnostic applications. Such innovations provide a scalable model for labs looking to increase throughput without the need for significant capital expenditure on new instrumentation.
What happens next
eGlint, Inc. is scheduled to launch a process-monitoring panel for cell therapy and antibody manufacturing in early Q1 2027.
Further reading
Learn more about the latest developments in the sector on the Biotech news page.
Source note: This article includes information reported by The Scientist.
Live Poll
Would you use an at-home diagnostic platform to monitor your protein biomarkers from your phone?
